Literature DB >> 35610346

An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.

Alice Nevone1,2, Maria Girelli1,2, Silvia Mangiacavalli3, Bruno Paiva4, Paolo Milani1,2, Pasquale Cascino1,2, Maggie Piscitelli1,2, Valentina Speranzini5, Claudio Salvatore Cartia3, Pietro Benvenuti2,3, Ibai Goicoechea4, Francesca Fazio6, Marco Basset1,2, Andrea Foli1,2, Martina Nanci1,2, Giulia Mazzini1,2, Serena Caminito1,2, Melania Antonietta Sesta1,2, Simona Casarini1,2, Paola Rognoni1,2, Francesca Lavatelli1,2, Maria Teresa Petrucci6, Pier Paolo Olimpieri7, Stefano Ricagno5,8, Luca Arcaini1,3, Giampaolo Merlini1,2, Giovanni Palladini9,10, Mario Nuvolone11,12.   

Abstract

Immunoglobulin light chain (AL) amyloidosis is caused by a small, minimally proliferating B-cell/plasma-cell clone secreting a patient-unique, aggregation-prone, toxic light chain (LC). The pathogenicity of LCs is encrypted in their sequence, yet molecular determinants of amyloidogenesis are poorly understood. Higher rates of N-glycosylation among clonal κ LCs from patients with AL amyloidosis compared to other monoclonal gammopathies indicate that this post-translational modification is associated with a higher risk of developing AL amyloidosis. Here, we exploited LC sequence information from previously published amyloidogenic and control clonal LCs and from a series of 220 patients with AL amyloidosis or multiple myeloma followed at our Institutions to define sequence and spatial features of N-glycosylation, combining bioinformatics, biochemical, proteomics, structural and genetic analyses. We found peculiar sequence and spatial pattern of N-glycosylation in amyloidogenic κ LCs, with most of the N-glycosylation sites laying in the framework region 3, particularly within the E strand, and consisting mainly of the NFT sequon, setting them apart with respect to non-amyloidogenic clonal LCs. Our data further support a potential role of N-glycosylation in determining the pathogenic behavior of a subset of amyloidogenic LCs and may help refine current N-glycosylation-based prognostic assessments for patients with monoclonal gammopathies.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35610346     DOI: 10.1038/s41375-022-01599-w

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


  56 in total

1.  Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment.

Authors:  Vittorio Perfetti; Simona Casarini; Giovanni Palladini; Maurizio Colli Vignarelli; Catherine Klersy; Marta Diegoli; Edoardo Ascari; Giampaolo Merlini
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

2.  The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.

Authors:  Vittorio Perfetti; Giovanni Palladini; Simona Casarini; Valentina Navazza; Paola Rognoni; Laura Obici; Rosangela Invernizzi; Stefano Perlini; Catherine Klersy; Giampaolo Merlini
Journal:  Blood       Date:  2011-11-08       Impact factor: 22.113

3.  Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival.

Authors:  Tatiana Prokaeva; Brian Spencer; Maurya Kaut; Al Ozonoff; Gheorghe Doros; Lawreen H Connors; Martha Skinner; David C Seldin
Journal:  Arthritis Rheum       Date:  2007-11

4.  Polymorphism in a kappa I primary (AL) amyloid protein (BAN).

Authors:  F E Dwulet; T P O'Connor; M D Benson
Journal:  Mol Immunol       Date:  1986-01       Impact factor: 4.407

Review 5.  Systemic immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz
Journal:  Nat Rev Dis Primers       Date:  2018-10-25       Impact factor: 52.329

6.  The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.

Authors:  R L Comenzo; Y Zhang; C Martinez; K Osman; G A Herrera
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

7.  Glycosylation of immunoglobulin light chains associated with amyloidosis.

Authors:  L A Omtvedt; D Bailey; D V Renouf; M J Davies; N A Paramonov; S Haavik; G Husby; K Sletten; E F Hounsell
Journal:  Amyloid       Date:  2000-12       Impact factor: 7.141

8.  Four structural risk factors identify most fibril-forming kappa light chains.

Authors:  F J Stevens
Journal:  Amyloid       Date:  2000-09       Impact factor: 7.141

9.  AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences.

Authors:  Kip Bodi; Tatiana Prokaeva; Brian Spencer; Maurya Eberhard; Lawreen H Connors; David C Seldin
Journal:  Amyloid       Date:  2009-03       Impact factor: 7.141

10.  Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Tammy L Price-Troska; Cristine Allmer; Robert A Kyle; Morie A Gertz; Rafael Fonseca
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.